Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Small interfering RNA (siRNA) are short double-stranded RNA molecules, typically 21-25 nucleotides long. On June 13, 2022, Alnylam's siRNA drug Amvuttra® (Vutrisiran) was approved by the FDA for treating polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. As Alnylam's flagship product, Amvuttra generated $560 million in sales in 2023. Compared to Alnylam's Onpattro, Amvuttra has lower manufacturing costs, requires less frequent dosing, and offers convenient subcutaneous injection, potentially leading more patients to switch to Amvuttra. Over 20 companies globally are developing siRNA drugs, but Alnylam dominates the market with a robust patent strategy covering Amvuttra's core components, delivery agents, sequences, and modifications. Alnylam utilizes divisional and continuation applications to maintain extensive patent protection, serving as a model for siRNA drug patenting. This report focuses on siRNA drug patent searches, using Alnylam's Amvuttra as a case study to illustrate the research process. It also provides an overview of the latest patent landscapes in the U.S. and China.

Read →

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201

Antibody-Drug Conjugates (ADCs) have a tripartite structure: Antibody-Linker-Payload. Currently, 272 ADCs are in clinical trials worldwide. Despite the withdrawal of Belantamab mafodotin, 14 ADCs remain on the market. ADC development is highly competitive, with strategic patent deployment being critical. For example, DS-8201's patents on each component offer primary protection, while novel combinations and pharmacological properties drive patent iteration and extend market exclusivity. Comprehensive extraction and aggregation of these source, core, and iterative patents are essential for high-quality patent research reports to guide infringement analysis, biosimilar development, and investment strategies. This report focuses on ADC patent searches, using DS-8201 as a case study to outline the research process and map the latest patent landscapes in China and the United States.

Read →

BeiGene's Patent Research and Practical Operation Guide for Tislelizumab

In recent years, the rise of biologics is an established fact. Antibody drugs, such as Merck's PD-1 monoclonal antibody Keytruda, have become top-sellers. As a result, patent research on antibody drugs has gained importance. The goal is to compile comprehensive and accurate patent information to support infringement analysis, biosimilar development, investment, and R&D. High-quality patent research reports on antibody drugs now represent a core competitive advantage, playing a crucial role at various corporate stages. This research involves several coordinated steps: patent search, patent screening, clinical analysis, and concluding recommendations. The following sections will detail these steps.

Read →

A Guide to Investigating Aflibercept Sequence Patents

The "A Guide to Investigating Aflibercept Sequence Patents" provides an in-depth analysis of global Aflibercept sequence patents through detailed research. The guide consists of five sections: Preface, Introduction to Aflibercept, Practical Patent Search, Patent Analysis, and Conclusion. It aims to instruct readers on using the Bio database for drug sequence patent search and analysis. In August 2023, Regeneron Pharmaceuticals announced FDA approval for an 8 mg injection of Eylea (Aflibercept) for wAMD, DME, and DR, extending the injection interval from two months to four months. Initially approved in 2011, Eylea was developed by Regeneron and Bayer. Aflibercept is a fully human recombinant fusion protein that inhibits angiogenesis and vascular permeability by binding VEGF-A, VEGF-B, and PlGF. Its indications include ophthalmic diseases and metastatic colorectal cancer. To aid biomedical researchers in understanding Aflibercept's global development and IP protection, the guide leverages the Patsnap Bio sequence database. It covers practical aspects of sequence patent searches, including retrieval methods and analytical techniques. The guide further analyzes the global status and core patents of Aflibercept, providing comprehensive insights on its patent landscape.

Read →

Conjugate Targeted Drug Delivery Research

The report provides a rapid review and market overview of the global conjugate targeted drug delivery research, with a professional analysis of technology and barriers, including an in-depth analysis of national policies and an excellent summary of applications and patents.

Read →

Global Innovative Pharmaceuticals Investment and Financing Report (Feb. 2023)

In February, there were a total of 48 events in the global innovative pharmaceutical industry, with a financing amount of 1.04 billion US dollars. The report analyzes the worldwide investment and financing trends in the innovative drug sector in February and explains the 10 selected potential players in innovative drug companies.

Read →

Inhalation Preparations Drug Delivery Research

The report provides a rapid review and market overview of the global inhalation preparations drug delivery industry, with professional analysis of technology and barriers, including an in-depth analysis of national policies and an excellent summary of applications and patents.

Read →

Viral Vector Drug Delivery Research

The report provides a rapid review and market overview of the global viral vector drug delivery industry, with professional analysis of technology and barriers, including an in-depth analysis of national policies and an excellent summary of applications and patents.

Read →

Exosome Drug Delivery Research

The report provides a rapid review and market overview of the global exosome drug delivery industry, with professional analysis of technology and barriers, including in-depth analysis of national policies and an excellent summary of applications and patents.

Read →